Following is another very interesting and worthwhile read from The Moss Report which, although it does not mention PROSTATE CANCER research, it should, nevertheless be considered inclusive. The report does after all, refer to many other forms of cancer: breast, colon, kidney, lung, bowel, gastrointestinal and ovarian.

CANCER DRUG TRIALS: QUITTING WHILE YOU’RE AHEAD - PART I

From time to time you hear about a clinical trial for a new cancer treatment that proves so stunningly effective that evaluators are obliged to end the trial prematurely so that all the participating patients can share in the new breakthrough. Typically this kind of news is portrayed as an example of progress, a welcome glimmer of hope.

However, some cynics have quietly speculated that the real purpose of stopping such trials is not to ensure that the few hundred trial participants who are receiving the current standard treatment are given access to the new drug, but to massively benefit the drug companies sponsoring the trial. When a trial is halted prematurely, researchers are deprived of the opportunity to determine whether the drug in question might eventually prove less valuable if the trial were allowed to proceed to completion. Crudely put, by stopping clinical trials early, the trial directors might be quitting while they are ahead.

Click here for full article: http://www.cancerdecisions.com/042008.html

This entry was posted on Monday, April 21st, 2008 at 5:25 am and is filed under Informative Web-Sites, News Items. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.